StockData
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. (AEON) stock

AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.11−0.03 (-19.40%)

Close on Nov 17, 2026Market cap $5.66MP/E –Yield –

AEON Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AEON Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$19.86M. For fiscal 2025 it was -$12.80M, down 117.5% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.80M-117.5%
FY2024Dec 31, 2024$72.99M–
FY2022Dec 31, 2022-$48.43M–
FY2021Dec 31, 2021-$1.94M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.92M–
Q1 FY2026Mar 31, 2026-$5.93M–
Q4 FY2025Dec 31, 2025-$5.51M–
Q3 FY2025Sep 30, 2025-$2.49M–
Q2 FY2025Jun 30, 2025-$4.34M-102.8%
Q1 FY2025Mar 31, 2025-$462.00K–
Q4 FY2024Dec 31, 2024-$2.32M–
Q3 FY2024Sep 30, 2024-$4.02M–
Q2 FY2024Jun 30, 2024$153.47M–
Q1 FY2024Mar 31, 2024-$74.15M–
Q2 FY2023Jun 30, 2023-$13.97M–
Q1 FY2023Mar 31, 2023-$13.05M–
Q4 FY2022Dec 31, 2022-$15.03M–
Q3 FY2022Sep 30, 2022-$9.91M–
Q2 FY2022Jun 30, 2022-$427.20K–
Q1 FY2022Mar 31, 2022-$389.07K–
Q4 FY2021Dec 31, 2021-$885.74K–
Q3 FY2021Sep 30, 2021-$450.89K–
Q2 FY2021Jun 30, 2021-$398.44K–
Q1 FY2021Mar 31, 2021-$200.86K–

More AEON Biopharma figures

See a number that looks wrong?